Bavarian Nordic A/S aktie
BVNRY
StängtBavarian Nordic A/S
Market Cap
$2,129,036,544
Om Bavarian Nordic A/S aktie
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Företagsinformation
2900 Hellerup, Denmark
Analytikernas aktierekommendationer
Denna översikt ger en snabb insikt i hur analytiker bedömer aktiens potential baserat på deras senaste analyser och kursmål.